Filters
Reducing systolic blood pressure (SBP) to a target of less than 140 mm Hg does not appear to have any negative effects on diffusion-weighted imaging lesion frequency and volume in patients with acute intracerebral haemorrhage (ICH), as shown in ICHADAPT-2*.
New research presented at EHRA 2025 has shown that patients who have taken antidepressants for extended periods are at increased risk of sudden cardiac death.
A nerve-sparing technique decreases erectile dysfunction in men undergoing robot-assisted radical prostatectomy (RARP) for prostate cancer in a phase III study.
Semaglutide may also confer hepatoprotective benefits, with interim efficacy data from the ongoing phase III ESSENCE study showing that the glucagon-like peptide-1 (GLP-1) receptor agonist helps dial down disease activity in patients with metabolic dysfunction–associated steatohepatitis (MASH) and moderate-to-severe fibrosis.
Greater intrinsic motivation for engaging in healthy lifestyle behaviours appears to promote long-term postpartum weight reduction and may be a promising target for interventions, suggests a study.
Gynaecologic oncology patients with better sleep efficiency in the days before a surgical procedure are more likely to have fewer postoperative complications and require lower doses of opioid pain medication upon hospital discharge, according to a study.
For hospitalized individuals initiating treatment for alcohol use disorder (AUD), oral naltrexone is equally efficacious as the extended-release injectable formulation in terms of reducing heavy drinking days, as shown in a study.
In adult patients with treatment-naive neovascular age-related macular degeneration (nAMD), the use of faricimab shows superior anatomic outcome compared with aflibercept during the head-to-head dosing phase, reports a study.
Regular physical activity appears to protect against lower extremity lymphedema in endometrial cancer survivors, as reported in a study.
A recent study has found that dexamethasone delivers better outcomes than methotrexate (MTX) and ranibizumab in patients with persistent or recurrent uveitic macular oedema through 24 weeks. In addition, side effects are manageable.
